Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer
Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer
复制标题
DOI：
10.1245/aso.2005.09.018
复制
发表时间：
2005-10-01
影响因子：
3.7
通讯作者：
Tanaka, F
中科院分区：
文献类型：
--
作者：
Takenaka, K;Ishikawa, S;Tanaka, F
背景：具有Kazal基序的逆转诱导富含半胱氨酸蛋白(RECK)是一种新型的膜锚定基质金属蛋白酶抑制剂，实验研究表明RECK可通过抑制血管生成来抑制肿瘤进展。我们已经发现，在非小细胞肺癌(NSCLC)中，RECK表达增强与良好的预后显著相关。方法：对118例病理分期为IIIA的非小细胞肺癌患者进行回顾性研究。结果：原发灶中RECK强表达53例(44.9%)，其余65例弱表达。RECK-强肿瘤患者的5年生存率(42.9%)显著高于RECK-弱肿瘤患者(23.1%，P=0.017)。RECK表达降低与单个N_2结节受累患者的不良预后显著相关(P=.019)，但与多个N_2结节受累患者的预后无关(P=.440)。多变量分析证实，RECK表达降低是预测预后不良的独立且显著的因素(P=.031)。结论：RECK状态是NSCLC病理分期IIIA期的一个新的预后因素。
Background: Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a novel membrane-anchored matrix metalloproteinase inhibitor, and experimental studies have shown that RECK can suppress tumor progression through angiogenesis inhibition. We have already revealed that enhanced RECK expression is significantly correlated with a favorable prognosis in non-small-cell lung cancer (NSCLC). In this study, further analyses focused on pN2 disease were conducted to assess the clinical significance of RECK expression.Methods: A total of 118 patients with completely resected pathologic stage IIIA N2 NSCLC were retrospectively examined. RECK expression in the primary tumor, along with involved N2 nodes, was examined immunohistochemically.Results: RECK expression in the primary tumor was strong in 53 patients (44.9%) and was weak in the other 65 patients. The 5-year survival rate of patients with RECK-strong tumor (42.9%) was significantly higher than that of patients with RECK-weak tumor (23.1% P = .017). Reduced RECK expression significantly correlated with a poor prognosis for patients with a single N2 node involved (P = .019), but not for patients with multiple N2 nodes involved (P = .440). A multivariate analysis confirmed that reduced RECK expression was an independent and significant factor to predict a poor prognosis (P = .031). RECK expression in involved N2 nodes was significantly higher than in primary tumors (P < .001).Conclusions: RECK status was a novel prognostic factor in pathologic stage IIIA N2 NSCLC.